Physician profile
Jon C Poling
NPI 1386744282
$5,525.53
in general payments reported to CMS, 2019-2025
31 companies · $975 in 2025
The $975 reported for 2025 was more than what 83% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $539 · 2022: $1,442 · 2023: $946 · 2024: $1,624 · 2025: $975.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,545.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,544.52 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,011.51 | 2021-2025 | |
| Leo Pharma INC. | $727.33 | 2021-2025 | Adbry, Anzupgo |
| Revance Therapeutics, INC. | $691.81 | 2024-2025 | Daxxify |
| Galderma Laboratories, L.P. | $416.33 | 2022-2025 | Twyneo, Aklief, Nemluvio |
| Arcutis Biotherapeutics, INC. | $296.39 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $251.36 | 2022-2025 | Ebglyss, Olumiant, Taltz |
| Allergan, INC. | $220.07 | 2021-2022 | |
| Genzyme Corporation | $217.63 | 2022-2024 | |
| Merz North America, INC. | $163.26 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $152.56 | 2023-2024 | Sotyktu |
| Amgen INC. | $137.15 | 2022-2024 | Prolia, Evenity |
| Pfizer INC. | $134.93 | 2023 | |
| Incyte Corporation | $133.49 | 2022-2025 | Opzelura |
| Epi Health, LLC | $120.19 | 2021-2022 | |
| Mallinckrodt Hospital Products INC. | $106.26 | 2024-2025 | Acthar |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $97.89 | 2021-2025 | Austedo Xr, Austedo Xr |
| Mayne Pharma Commercial LLC | $95.49 | 2021-2025 | |
| Dermavant Sciences, INC. | $80.89 | 2024 | Vtama |
| Regeneron Healthcare Solutions, INC. | $80.56 | 2022-2025 | Dupixent |
| Organon LLC | $80.41 | 2025 | Vtama |
| Motiva USA, LLC | $60.72 | 2025 | |
| Ucb, INC. | $48.32 | 2024-2025 | Bimzelx |
| Biofrontera INC. | $44.59 | 2021-2024 | Ameluz, Rhodoled Xl, Xepi |
| Journey Medical Corporation | $33.13 | 2023 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.02 | 2022 | |
| Almirall LLC | $19.30 | 2025 | Klisyri |
| Novartis Pharmaceuticals Corporation | $18.65 | 2021 | |
| Janssen Biotech, INC. | $18.57 | 2022 | |
| Mentor Worldwide LLC | $16.45 | 2023 | Mentor Memorygel Resterilizable Gel Sizer |
| Paratek Pharmaceuticals, INC. | $14.95 | 2023 | Nuzyra |
| Sun Pharmaceutical Industries INC. | $13.32 | 2023 | Winlevi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jon Poling listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.